

Special Issue

Cutaneous Reactions to Vaccination: Clinical and Histopathological Features

Message from the Guest Editors

The advent of anti-SARS-CoV-2 mRNA vaccines has drastically reduced the morbidity and mortality associated with COVID-19, allowing a return to rather normal living conditions in a small number of months. Since the beginning of the vaccination campaign, vaccines have proven to be extremely effective in reducing complications during the disease, and there have been various reports of adverse events which, however, have been much lower than the benefits of vaccination. In this Special Issue, we intend to collect original articles, case reports, case series, reviews, and possible comments on this topic, with the hope of hosting scientific contributions that can stimulate discussion and herald new advances in this area.



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4

CiteScore 9.9

Indexed in PubMed



[mdpi.com/journal/vaccines](https://www.mdpi.com/journal/vaccines)

Vaccines

Editorial Office

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34

vaccines@mdpi.com

[mdpi.com/journal/vaccines](https://www.mdpi.com/journal/vaccines)

Guest Editors

Dr. Gerardo Cazzato

Section of Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", 70124 Bari, Italy

Dr. Francesca Ambrogio

Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", Bari, Italy

Deadline for manuscript submissions

closed (31 December 2024)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](http://mdpi.com/journal/vaccines)

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

